EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma

Matthew E. Randolph, Megan M. Cleary, Zia Bajwa, Matthew N. Svalina, Michael C. Young, Atiya Mansoor, Pali Kaur, Carol J. Bult, Martin W. Goros, Joel E. Michalek, Sunny Xiang, James Keck, Valery Krasnoperov, Parkash Gill, Charles Keller

Research output: Contribution to journalArticle

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma affecting children and is often diagnosed with concurrent metastases. Unfortunately, few effective therapies have been discovered that improve the long-term survival rate for children with metastatic disease. Here we determined effectiveness of targeting the receptor tyrosine kinase, EphB4, in both alveolar and embryonal RMS either directly through the inhibitory antibody, VasG3, or indirectly by blocking both forward and reverse signaling of EphB4 binding to EphrinB2, cognate ligand of EphB4. Clinically, EphB4 expression in eRMS was correlated with longer survival. Experimentally, inhibition of EphB4 with VasG3 in both aRMS and eRMS orthotopic xenograft and allograft models failed to alter tumor progression. Inhibition of EphB4 forward signaling using soluble EphB4 protein fused with murine serum albumin failed to affect eRMS model tumor progression, but did moderately slow progression in murine aRMS. We conclude that inhibition of EphB4 signaling with these agents is not a viable monotherapy for rhabdomyosarcoma.

Original languageEnglish (US)
Article numbere0183161
JournalPLoS One
Volume12
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Rhabdomyosarcoma
Alveolar Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma
therapeutics
neoplasms
allografting
Tumors
mice
sarcoma
Receptor Protein-Tyrosine Kinases
serum albumin
Heterografts
Serum Albumin
metastasis
Sarcoma
Allografts
tyrosine
Neoplasms
phosphotransferases (kinases)
survival rate

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Randolph, M. E., Cleary, M. M., Bajwa, Z., Svalina, M. N., Young, M. C., Mansoor, A., ... Keller, C. (2017). EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. PLoS One, 12(8), [e0183161]. https://doi.org/10.1371/journal.pone.0183161

EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. / Randolph, Matthew E.; Cleary, Megan M.; Bajwa, Zia; Svalina, Matthew N.; Young, Michael C.; Mansoor, Atiya; Kaur, Pali; Bult, Carol J.; Goros, Martin W.; Michalek, Joel E.; Xiang, Sunny; Keck, James; Krasnoperov, Valery; Gill, Parkash; Keller, Charles.

In: PLoS One, Vol. 12, No. 8, e0183161, 01.08.2017.

Research output: Contribution to journalArticle

Randolph, ME, Cleary, MM, Bajwa, Z, Svalina, MN, Young, MC, Mansoor, A, Kaur, P, Bult, CJ, Goros, MW, Michalek, JE, Xiang, S, Keck, J, Krasnoperov, V, Gill, P & Keller, C 2017, 'EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma', PLoS One, vol. 12, no. 8, e0183161. https://doi.org/10.1371/journal.pone.0183161
Randolph ME, Cleary MM, Bajwa Z, Svalina MN, Young MC, Mansoor A et al. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. PLoS One. 2017 Aug 1;12(8). e0183161. https://doi.org/10.1371/journal.pone.0183161
Randolph, Matthew E. ; Cleary, Megan M. ; Bajwa, Zia ; Svalina, Matthew N. ; Young, Michael C. ; Mansoor, Atiya ; Kaur, Pali ; Bult, Carol J. ; Goros, Martin W. ; Michalek, Joel E. ; Xiang, Sunny ; Keck, James ; Krasnoperov, Valery ; Gill, Parkash ; Keller, Charles. / EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. In: PLoS One. 2017 ; Vol. 12, No. 8.
@article{aa9790b9b1cb4c3992a54109bf38f30a,
title = "EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma",
abstract = "Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma affecting children and is often diagnosed with concurrent metastases. Unfortunately, few effective therapies have been discovered that improve the long-term survival rate for children with metastatic disease. Here we determined effectiveness of targeting the receptor tyrosine kinase, EphB4, in both alveolar and embryonal RMS either directly through the inhibitory antibody, VasG3, or indirectly by blocking both forward and reverse signaling of EphB4 binding to EphrinB2, cognate ligand of EphB4. Clinically, EphB4 expression in eRMS was correlated with longer survival. Experimentally, inhibition of EphB4 with VasG3 in both aRMS and eRMS orthotopic xenograft and allograft models failed to alter tumor progression. Inhibition of EphB4 forward signaling using soluble EphB4 protein fused with murine serum albumin failed to affect eRMS model tumor progression, but did moderately slow progression in murine aRMS. We conclude that inhibition of EphB4 signaling with these agents is not a viable monotherapy for rhabdomyosarcoma.",
author = "Randolph, {Matthew E.} and Cleary, {Megan M.} and Zia Bajwa and Svalina, {Matthew N.} and Young, {Michael C.} and Atiya Mansoor and Pali Kaur and Bult, {Carol J.} and Goros, {Martin W.} and Michalek, {Joel E.} and Sunny Xiang and James Keck and Valery Krasnoperov and Parkash Gill and Charles Keller",
year = "2017",
month = "8",
day = "1",
doi = "10.1371/journal.pone.0183161",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma

AU - Randolph, Matthew E.

AU - Cleary, Megan M.

AU - Bajwa, Zia

AU - Svalina, Matthew N.

AU - Young, Michael C.

AU - Mansoor, Atiya

AU - Kaur, Pali

AU - Bult, Carol J.

AU - Goros, Martin W.

AU - Michalek, Joel E.

AU - Xiang, Sunny

AU - Keck, James

AU - Krasnoperov, Valery

AU - Gill, Parkash

AU - Keller, Charles

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma affecting children and is often diagnosed with concurrent metastases. Unfortunately, few effective therapies have been discovered that improve the long-term survival rate for children with metastatic disease. Here we determined effectiveness of targeting the receptor tyrosine kinase, EphB4, in both alveolar and embryonal RMS either directly through the inhibitory antibody, VasG3, or indirectly by blocking both forward and reverse signaling of EphB4 binding to EphrinB2, cognate ligand of EphB4. Clinically, EphB4 expression in eRMS was correlated with longer survival. Experimentally, inhibition of EphB4 with VasG3 in both aRMS and eRMS orthotopic xenograft and allograft models failed to alter tumor progression. Inhibition of EphB4 forward signaling using soluble EphB4 protein fused with murine serum albumin failed to affect eRMS model tumor progression, but did moderately slow progression in murine aRMS. We conclude that inhibition of EphB4 signaling with these agents is not a viable monotherapy for rhabdomyosarcoma.

AB - Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma affecting children and is often diagnosed with concurrent metastases. Unfortunately, few effective therapies have been discovered that improve the long-term survival rate for children with metastatic disease. Here we determined effectiveness of targeting the receptor tyrosine kinase, EphB4, in both alveolar and embryonal RMS either directly through the inhibitory antibody, VasG3, or indirectly by blocking both forward and reverse signaling of EphB4 binding to EphrinB2, cognate ligand of EphB4. Clinically, EphB4 expression in eRMS was correlated with longer survival. Experimentally, inhibition of EphB4 with VasG3 in both aRMS and eRMS orthotopic xenograft and allograft models failed to alter tumor progression. Inhibition of EphB4 forward signaling using soluble EphB4 protein fused with murine serum albumin failed to affect eRMS model tumor progression, but did moderately slow progression in murine aRMS. We conclude that inhibition of EphB4 signaling with these agents is not a viable monotherapy for rhabdomyosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=85029160947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029160947&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0183161

DO - 10.1371/journal.pone.0183161

M3 - Article

C2 - 28817624

AN - SCOPUS:85029160947

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0183161

ER -